A58V

Category 5 — IDR ExclusionConflictingCytoplasmic · predictedEditorial

Alanine → Valine at position 58 · N-terminal intrinsically disordered region (1-86) · WFS1 (Wolframin)

Ala→Val p58 IDR AM=0.09 ddg=-0.68 pLDDT=26. ClinVar Conflicting evidence. Atlas mechanism: see structural analysis.

Interactive 3D Structure

Wild-type reference

Wild-type A58 — native residue, no strong sidechain contacts

Fullscreen ↗

DynaMut2 mutant · A58V

Mutant V58 — energy-minimized; local contact network preserved

Fullscreen ↗

Computational Predictions

DynaMut2 ΔΔG

-0.68kcal/mol

Destabilising — mild

AlphaMissense

0.087

LBen

AlphaFold pLDDT

model confidence

Schema

Cat 5

Category 5 — IDR Exclusion

Clinical Evidence

ClinVar classificationConflicting classifications of pathogenicity

Review statuscriteria provided, conflicting classifications

Associated conditions(no specific conditions catalogued)

InheritanceConflicting ClinVar classifications.

Population frequency (gnomAD v4)Ultra-rare · AF 0.0053%

cDNA changec.173C>T

ClinVar accessionVCV000516852

Last evaluated2026/01/07 00:00

Observed at very low frequency in gnomAD.

Structural Context

Position analysis: ALA59 (2.5 Å), ALA57 (2.5 Å — partner of A57S/A57T). pLDDT 26 deep IDR. Multiple A57 substitutions Atlas-tracked. The Atlas's neighbor extraction surfaces this variant's contacts and connects them to the broader multi-variant target landscape.

Amino-acid chemistry

conservative volume increase

Position in the protein

N-terminal IDR

Druggability Assessment

Cat 5 IDR — see structural prose. AlphaMissense below threshold (AM under-call class) but mechanism is structurally identified. Therapeutic strategy: site-directed at contacts identified above, or wet-lab validation if pLDDT borderline/below 50.

Why this matters

Deep IDR — multi-substitution position cluster 57-58.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the A58V PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download A58V PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1–890 · Wolframin

Region1–321 · Interaction with ATP6V1A

Region1–86 · Disordered

Natural variant58–58 · in WFS1; dbSNP:rs369671890